CELGENE-GC-LTFU-001
Phase II/III
OPEN TO ACCRUAL
Long-Term Follow-Up Protocol for Subjects Treated with Gene-Modified T Cells
GRACELL-GC012F-CD19-BCMA-001
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Study of GC012F, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects with Relapsed/Refractory Multiple Myeloma
GSK-3377794-LTFU
Phase I
OPEN TO ACCRUAL
Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
IIT-SHAH-IL7-IL15-CD20-19
Phase I/II
OPEN TO ACCRUAL
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
JNJ-MY4002-CARTINUE-LTFU
Phase IV
OPEN TO ACCRUAL
Long-Term Follow-Up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
JUNO-017004-TRANSCEND-CLL
Phase I/II
OPEN TO ACCRUAL
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)